ELOC

Across TCGA pan-cancer cohorts, ELOC mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ELOC data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ELOC mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELOC expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ELOC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.554	0.889	.001	52	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
LUAD	DFS	Median	II,III,IV	0.870	0.417	.017	5	view →
UCEC	DFS	Tertile	III,IV	1.000	0.487	.049	4	view →
LSCC	OS	Tertile	II,III,IV	0.723	1.000	.044	2	view →
HNSC	DFS	Median	IV	0.891	0.646	.010	2	view →
GBM	OS	Quartile	All	0.705	0.977	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ELOC–CCRCC (DFS)

Open the CCRCC breakdown →